TACT908

Last updated

TACT908
TACT908.svg
Clinical data
Other namesTACT-908; Compound 28-12; 2ZEDMA; [2-(Indolizin-1-yl)ethyl]dimethylamine; Indolizine-DMT
Drug class Serotonin receptor agonist; Serotonin 5-HT1B receptor agonist; Non-hallucinogenic serotonin 5-HT2A receptor agonist
Identifiers
  • 2-indolizin-1-yl-N,N-dimethylethanamine
PubChem CID
Chemical and physical data
Formula C12H16N2
Molar mass 188.274 g·mol−1
3D model (JSmol)
  • CN(C)CCC1=C2C=CC=CN2C=C1
  • InChI=1S/C12H16N2/c1-13(2)9-6-11-7-10-14-8-4-3-5-12(11)14/h3-5,7-8,10H,6,9H2,1-2H3
  • Key:CBZZXMYTGARRHB-UHFFFAOYSA-N

TACT908, also known as [2-(indolizin-1-yl)ethyl]dimethylamine (2ZEDMA), is a serotonin receptor agonist which is under development for the treatment of cluster headaches. [1] [2] [3] It is an analogue and positional isomer of the tryptamine serotonergic psychedelic N,N-dimethyltryptamine (DMT) in which the indole ring has been replaced with an indolizine ring. [1]

The drug acts as a serotonin 5-HT1B and 5-HT2A receptor agonist. [1] [3] Its EC50 Tooltip half-maximal effective concentration at the serotonin 5-HT2A receptor is 52 nM (Emax Tooltip maximal efficacy ≈ 30% of that of serotonin) and its EC50 at the serotonin 5-HT1B receptor is 143 nM. [1] TACT908 is said to be a non-hallucinogenic serotonin 5-HT2A receptor agonist. [1] [3] It showed little or no activity at 45 other screened targets, including the serotonin 5-HT1A, 5-HT2B, and 5-HT3 receptors as well as the monoamine transporters (MATs). [1] Other serotonin receptors besides the preceding, such as the serotonin 5-HT2C receptor, were not assessed. [1] The drug was a weak monoamine oxidase inhibitor (MAOI), specifically of monoamine oxidase A (MAO-A) (IC50 Tooltip half-maximal inhibitory concentration = 7,252 nM). [1]

TACT908 is under development by Tactogen. [1] [2] [3] It was patented by Matthew Baggott and Tactogen in 2023. [1] As of January 2025, the drug is in preclinical research for cluster headaches. [2] [3]

The α-methyl and N-desmethyl analogue of TACT908, 1ZP2MA ([1-(indolizin-1-yl)propan-2-yl](methyl)amine or 1-(indolizin-1-yl)-N-methylpropan-2-amine), has also been characterized and described. [1] It is the indolizine analogue of α,N-dimethyltryptamine (α,N-DMT or N-methyl-αMT). [1] 1ZP2MA was found to be a potent dopamine releasing agent, with an EC50 of 62 nM. [1]

See also

Related Research Articles

<span class="mw-page-title-main">Tryptamine</span> Metabolite of the amino acid tryptophan

Tryptamine is an indolamine metabolite of the essential amino acid tryptophan. The chemical structure is defined by an indole—a fused benzene and pyrrole ring, and a 2-aminoethyl group at the second carbon. The structure of tryptamine is a shared feature of certain aminergic neuromodulators including melatonin, serotonin, bufotenin and psychedelic derivatives such as dimethyltryptamine (DMT), psilocybin, psilocin and others.

<span class="mw-page-title-main">5-MeO-DMT</span> Chemical compound

5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), also known as O-methylbufotenin or mebufotenin, is a naturally occurring psychedelic of the tryptamine family. It is found in a wide variety of plant species, and is also secreted by the glands of at least one toad species, the Colorado River toad. It may occur naturally in humans as well. Like its close relatives dimethyltryptamine (DMT) and bufotenin (5-HO-DMT), it has been used as an entheogen in South America. Slang terms include five-methoxy, the power, bufo, and toad venom.

<span class="mw-page-title-main">5-MeO-AMT</span> Chemical compound

5-MeO-αMT, or 5-methoxy-α-methyltryptamine, also known as α,O-dimethylserotonin (Alpha-O), is a serotonergic psychedelic of the tryptamine family. It is a derivative of α-methyltryptamine (αMT) and an analogue of 5-MeO-DMT.

<span class="mw-page-title-main">Serotonin receptor agonist</span> Neurotransmission-modulating substance

A serotonin receptor agonist is an agonist of one or more serotonin receptors. They activate serotonin receptors in a manner similar to that of serotonin, a neurotransmitter and hormone and the endogenous ligand of the serotonin receptors.

<span class="mw-page-title-main">5-Methoxytryptamine</span> Chemical compound

5-Methoxytryptamine, also known as serotonin methyl ether or O-methylserotonin and as mexamine, is a tryptamine derivative closely related to the neurotransmitters serotonin and melatonin. It has been shown to occur naturally in the body in low levels, especially in the pineal gland. It is formed via O-methylation of serotonin or N-deacetylation of melatonin.

α,<i>N</i>-DMT Chemical compound

α,N-Dimethyltryptamine (α,N-DMT; developmental code names SK&F-7024, Ro 3-1715), also known as N-methyl-α-methyltryptamine (N-methyl-αMT), is a lesser-known substituted tryptamine and psychoactive drug. It is the α,N-dimethyl positional isomer of N,N-dimethyltryptamine (N,N-DMT).

<span class="mw-page-title-main">5-Fluoro-AMT</span> Chemical compound

5-Fluoro-α-methyltryptamine, also known as PAL-212 or PAL-544, is a putative stimulant, entactogen, and psychedelic tryptamine derivative related to α-methyltryptamine (αMT).

<span class="mw-page-title-main">Serotonin–dopamine releasing agent</span> Drug that releases serotonin and dopamine in the brain

A serotonin–dopamine releasing agent (SDRA) is a type of drug which induces the release of serotonin and dopamine in the body and/or brain.

<span class="mw-page-title-main">Substituted tryptamine</span> Class of indoles

Substituted tryptamines, or simply tryptamines, also known as serotonin analogues (i.e., 5-hydroxytryptamine analogues), are organic compounds which may be thought of as being derived from tryptamine itself. The molecular structures of all tryptamines contain an indole ring, joined to an amino (NH2) group via an ethyl (−CH2–CH2−) sidechain. In substituted tryptamines, the indole ring, sidechain, and/or amino group are modified by substituting another group for one of the hydrogen (H) atoms.

<span class="mw-page-title-main">5-Chloro-αMT</span> Chemical compound

5-Chloro-α-methyltryptamine (5-Chloro-αMT), also known as PAL-542, is a tryptamine derivative related to α-methyltryptamine (αMT) and one of only a few known serotonin–dopamine releasing agents (SDRAs). It is also a potent serotonin 5-HT2A receptor agonist and hence may be a serotonergic psychedelic. The drug has been investigated in animals as a potential treatment for cocaine dependence.

<span class="mw-page-title-main">5-Fluoro-AET</span> Chemical compound

5-Fluoro-AET, also known as 5-fluoro-α-ethyltryptamine or by the code name PAL-545, is a substituted tryptamine derivative which acts as a serotonin–dopamine releasing agent (SDRA) and as an agonist of the serotonin 5-HT2A receptor.

<span class="mw-page-title-main">BK-NM-AMT</span> Monoamine releaser and entactogen

BK-NM-AMT, or βk-NM-αMT, also known as β-keto-N-methyl-αMT or α,N-dimethyl-β-ketotryptamine, as well as 3-indoylmethcathinone, is a serotonin–dopamine releasing agent (SDRA) and putative entactogen of the tryptamine, α-alkyltryptamine, and β-ketotryptamine families. Along with certain other tryptamines, such as α-ethyltryptamine (αET), 5-chloro-αMT and 5-fluoro-αET, it is one of the few SDRAs known.

α-Methylisotryptamine Monoaminergic drug

α-Methylisotryptamine is a synthetic compound belonging to the tryptamine class, known for its psychoactive properties. As a structural analog of α-methyltryptamine (αMT), isoAMT exhibits entactogenic and psychedelic effects.

isoDMT Serotonergic drug

isoDMT, also known as N,N-dimethylisotryptamine, is a putatively non-hallucinogenic serotonin 5-HT2A receptor agonist and psychoplastogen of the isotryptamine group. It is the isotryptamine homologue of dimethyltryptamine (DMT), a more well-known serotonergic psychedelic of the tryptamine family, and represents a small structural modification of DMT.

<span class="mw-page-title-main">5-Chloro-αET</span> Pharmaceutical compound

5-Chloro-αET, or 5-chloro-AET, also known as 5-chloro-α-ethyltryptamine, is a serotonergic agent of the tryptamine and α-alkyltryptamine families. It is the derivative of α-ethyltryptamine with a 5-chloro substitution. Analogues of 5-chloro-αET include 5-fluoro-αET, 5-chloro-αMT, and 5-fluoro-αMT.

<span class="mw-page-title-main">1ZP2MA</span> Pharmaceutical compound

1ZP2MA, also known as [1-(indolizin-1-yl)propan-2-yl](methyl)amine or as 1-(indolizin-1-yl)-N-methylpropan-2-amine, is a monoamine releasing agent and an indolizine derivative. It is the analogue and positional isomer of the stimulant-like drug α,N-dimethyltryptamine (α,N-DMT or N-methyl-α-methyltryptamine (N-methyl-αMT)) in which the indole ring has been replaced with an indolizine ring. 1ZP2MA has been found to be a potent dopamine releasing agent, with an EC50 of 62 nM. It is the α-methyl and N-desmethyl analogue of (2-(indolizin-1-yl)ethyl)dimethylamine (TACT908; the indolizine analogue of dimethyltryptamine (DMT)). 1ZP2MA and 2ZEDMA were patented by Tactogen in 2023.

<span class="mw-page-title-main">1Z2MAP1O</span> Pharmaceutical compound

1Z2MAP1O, also known as 1-(indolizin-3-yl)-2-(methylamino)propan-1-one, is a monoamine releasing agent and serotonin receptor modulator and an indolizine derivative. It is an analogue of BK-NM-AMT (β-keto-N-methyl-α-methyltryptamine) in which the indole ring has been replaced with an indolizine ring.

<span class="mw-page-title-main">3-APBT</span> Pharmaceutical compound

3-APBT, also known as 3-(2-aminopropyl)benzo[β]thiophene, is a monoamine releasing agent and serotonin receptor agonist of the benzothiophene group. It is an analogue of α-methyltryptamine (AMT) in which the indole ring has been replaced with a benzothiophene ring.

<span class="mw-page-title-main">3-APB</span> Pharmaceutical compound

3-APB, also known as 3-(2-aminopropyl)benzofuran, is a drug of the benzofuran family related to α-methyltryptamine (AMT). It is an analogue of AMT in which the indole ring has been replaced with a benzofuran ring.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 WOpatent 2023183613A2, Matthew J. Baggott,"Indolizine compounds for the treatment of mental disorders or inflammation",published 2023 September 28, assigned to Tactogen
  2. 1 2 3 Haichin M (2024). "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 29 January 2025.
  3. 1 2 3 4 5 "Tactogen Inc – Pipeline". Tactogen Inc. Tactogen. 8 February 2021. Retrieved 29 January 2025. OUR PIPELINE: [...] COMPOUND: TACT908. TARGETS: 5-HT1B, 5-HT2A ***. INDICATION: Cluster Headache. Prevalence: 0.24%. STATUS: Preclinical. [...] ***Partial agonist at 2A, non-hallucinogenic.